Geron Corporation Asset Resilience Ratio
Geron Corporation asset resilience ratio. Geron Corporation (GERN) has an Asset Resilience Ratio of 45.90% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Geron Corporation to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Geron Corporation (2000–2025)
Asset resilience ratio of Geron Corporation from 2000 to 2025. This chart shows how Geron Corporation's Asset Resilience Ratio has changed over time. Read GERN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Geron Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Geron Corporation asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $238.21 Million | 45.9% |
| Total Liquid Assets | $238.21 Million | 45.90% |
Asset Resilience Insights
- Very High Liquidity: Geron Corporation maintains exceptional liquid asset reserves at 45.90% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Geron Corporation Industry Peers by Asset Resilience Ratio
Compare Geron Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Geron Corporation Asset Resilience Ratio by Year (2000–2025)
Geron Corporation asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Geron Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 49.14% | $280.36 Million | $570.54 Million | -6.02pp |
| 2024-12-31 | 55.16% | $327.55 Million | $593.78 Million | -11.75pp |
| 2023-12-31 | 66.91% | $263.68 Million | $394.08 Million | +6.09pp |
| 2022-12-31 | 60.82% | $115.90 Million | $190.57 Million | -5.04pp |
| 2021-12-31 | 65.85% | $148.85 Million | $226.03 Million | -2.98pp |
| 2020-12-31 | 68.83% | $186.35 Million | $270.73 Million | -7.10pp |
| 2019-12-31 | 75.93% | $125.68 Million | $165.52 Million | -6.49pp |
| 2018-12-31 | 82.42% | $152.71 Million | $185.28 Million | +11.40pp |
| 2017-12-31 | 71.03% | $78.35 Million | $110.31 Million | -7.31pp |
| 2016-12-31 | 78.34% | $102.03 Million | $130.25 Million | +16.14pp |
| 2015-12-31 | 62.20% | $92.52 Million | $148.76 Million | -0.78pp |
| 2014-12-31 | 62.98% | $108.64 Million | $172.51 Million | -14.58pp |
| 2013-12-31 | 77.56% | $52.23 Million | $67.34 Million | +3.94pp |
| 2012-12-31 | 73.62% | $73.47 Million | $99.80 Million | +7.88pp |
| 2011-12-31 | 65.74% | $105.21 Million | $160.05 Million | +5.54pp |
| 2010-12-31 | 60.19% | $140.60 Million | $233.58 Million | +17.50pp |
| 2009-12-31 | 42.69% | $77.01 Million | $180.38 Million | +12.34pp |
| 2008-12-31 | 30.36% | $53.49 Million | $176.22 Million | +2.95pp |
| 2007-12-31 | 27.40% | $59.98 Million | $218.90 Million | -7.68pp |
| 2006-12-31 | 35.08% | $77.45 Million | $220.80 Million | -11.55pp |
| 2005-12-31 | 46.63% | $93.84 Million | $201.24 Million | -36.87pp |
| 2004-12-31 | 83.50% | $110.12 Million | $131.87 Million | +1.86pp |
| 2003-12-31 | 81.64% | $96.43 Million | $118.11 Million | +11.78pp |
| 2002-12-31 | 69.86% | $42.38 Million | $60.67 Million | +17.72pp |
| 2001-12-31 | 52.13% | $50.17 Million | $96.23 Million | +49.47pp |
| 2000-12-31 | 2.67% | $3.04 Million | $114.03 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more